AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24742013 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 24742013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study 24742768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg/d
Number of subjects: 35
Study 24742768 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 35
Study 24742874 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity assessed by counts/minute (median 244.37)
Number of subjects: 263
Study 24742874 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous activity daytime
Number of subjects: 263
Study 24742874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary activity daytime
Number of subjects: 263
Study 24742874 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and vigorous activity
Number of subjects: 263
Study 24743000 — intervention group
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG (0.100 mg/kg)
Number of subjects: 25
Study 24743391 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term parenteral nutrition (PN)
Number of subjects: 27
Study 24743708 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line trastuzumab use
Number of subjects: 244
Study 24743708 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line taxane use
Number of subjects: 244
Study 24743708 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-positive MBC patient profile
Number of subjects: 244
Study 24743708 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 244
Study 24743713 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram/Escitalopram for up to 8 weeks
Number of subjects: 0
Study 24743720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' rated illness severity scores
Number of subjects: 0
Study 24743720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' rated illness severity scores
Number of subjects: 0
Study 24744276 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary artery (IMA) occlusion during coronary artery balloon occlusion
Number of subjects: 120
Study 24744276 — intervention group
Group type: COMPARATOR
Intervention: No IMA occlusion during coronary artery balloon occlusion
Number of subjects: 120
Study 24744276 — intervention group
Group type: EXPERIMENTAL
Intervention: Left IMA with left anterior descending artery occlusion
Number of subjects: 120
Study 24744276 — intervention group
Group type: EXPERIMENTAL
Intervention: Right IMA with right coronary artery occlusion
Number of subjects: 120
Study 24744276 — intervention group
Group type: EXPERIMENTAL
Intervention: Right IMA with left anterior descending artery occlusion
Number of subjects: 120
Study 24744276 — intervention group
Group type: EXPERIMENTAL
Intervention: Left IMA with right coronary artery occlusion
Number of subjects: 120
Study 24744276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral IMA occlusions
Number of subjects: 120
Study 24744276 — intervention group
Group type: COMPARATOR
Intervention: Contralateral IMA occlusions
Number of subjects: 120
Study 24744276 — intervention group
Group type: EXPERIMENTAL
Intervention: Left circumflex artery occlusions with either IMA
Number of subjects: 120
Study 24745306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 74
Study 24745306 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery index
Number of subjects: 74
Study 24745306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 74
Study 24745306 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 74
Study 24746173 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 24746569 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers (CEA, CA19-9, LDH, CRP, IL-6, IL-8, CA IX, osteopontin, 25-OH-vitamin D)
Number of subjects: 295
Study 24746569 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers (CEA, IL-8, osteopontin)
Number of subjects: 295
Study 24746569 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 295
Study 24746569 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA and IL-8
Number of subjects: 295
Study 24746569 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker model
Number of subjects: 295
Study 24746650 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold (BVS)
Number of subjects: 136
Study 24746650 — intervention group
Group type: COMPARATOR
Intervention: everolimus-eluting metal stents (EES)
Number of subjects: 136
Study 24746841 — intervention group
Group type: EXPERIMENTAL
Intervention: MABp1 (anti-interleukin-1α monoclonal antibody) at 3.75 mg/kg every 2 weeks
Number of subjects: 52
Study 24746841 — intervention group
Group type: EXPERIMENTAL
Intervention: MABp1 (anti-interleukin-1α monoclonal antibody)
Number of subjects: 52
Study 24747207 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in undifferentiated pleomorphic sarcoma (UPS)
Number of subjects: 183
Study 24747207 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in leiomyosarcoma
Number of subjects: 183
Study 24747207 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in synovial sarcoma
Number of subjects: 183
Study 24747207 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in liposarcoma
Number of subjects: 183
Study 24747207 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in angiosarcoma
Number of subjects: 183
Study 24747207 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) expression in MPNST
Number of subjects: 183
Study 24747207 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of p16(INK4a) in high grade sarcomas
Number of subjects: 183
Study 24747207 — intervention group
Group type: EXPERIMENTAL
Intervention: Demethylation treatment with 5-aza-2'-deoxycytide
Number of subjects: 183
Study 24747441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 24747441 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 0
Study 24747949 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² × 4 infusions) combined with three cycles of dexamethasone (28 mg/m², max. 40 mg) for 4 days at 2-week intervals
Number of subjects: 67
Study 24747949 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 67
Study 24747949 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone
Number of subjects: 67
Study 24747949 — intervention group
Group type: COMPARATOR
Intervention: Rituximab with one cycle of dexamethasone
Number of subjects: 67
Study 24748496 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor KIR B haplotypes
Number of subjects: 1532
Study 24748496 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor KIR B haplotypes with recipient C1-bearing HLA-C allotypes
Number of subjects: 1532
Study 24748496 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more donor KIR B motifs with recipient C1
Number of subjects: 1532
Study 24748496 — intervention group
Group type: COMPARATOR
Intervention: C1/x recipients
Number of subjects: 1532
Study 24748824 — intervention group
Group type: EXPERIMENTAL
Intervention: New disposable injection pen (GoQuick(®), Pfizer, Inc.)
Number of subjects: 119
Study 24748824 — intervention group
Group type: COMPARATOR
Intervention: Current reusable pen (GENOTROPIN Pen(®), Pfizer, Inc.)
Number of subjects: 119
Study 24750460 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II LVAD
Number of subjects: 1125
Study 24750693 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental self-efficacy scale for helping their child get at least 60 minutes of moderate intensity physical activity every day
Number of subjects: 304
Study 24750693 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental self-efficacy scale for helping one's child consume five servings of fruits and vegetables each day
Number of subjects: 304
Study 24750693 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental self-efficacy scale for limiting sugary drinks to once a week
Number of subjects: 304
Study 24750693 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental self-efficacy scale for limiting consumption of fruit juice to 6 ounces every day
Number of subjects: 304
Study 24751453 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg weekly for 45 weeks
Number of subjects: 11
Study 24751516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of ischemic heart disease (IHD+)
Number of subjects: 4169
Study 24751516 — intervention group
Group type: COMPARATOR
Intervention: Patients without a history of ischemic heart disease (IHD-)
Number of subjects: 4169
Study 24751516 — intervention group
Group type: EXPERIMENTAL
Intervention: IHD+ patients
Number of subjects: 4169
Study 24751516 — intervention group
Group type: COMPARATOR
Intervention: IHD- patients
Number of subjects: 4169
Study 24752047 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 326
Study 24752047 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT)
Number of subjects: 326
Study 24752449 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2523355 (litronesib) at 2 mg/m²/day
Number of subjects: 12
Study 24752449 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2523355 (litronesib) at 4 mg/m²/day
Number of subjects: 12
Study 24752449 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2523355 (litronesib) at 5 mg/m²/day
Number of subjects: 12
Study 24752449 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2523355 (litronesib)
Number of subjects: 12
Study 24752945 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of cisplatin and gemcitabine
Number of subjects: 81
Study 24752945 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 81
Study 24753053 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 205
Study 24753053 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 205
Study 24753053 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat stenting
Number of subjects: 205
Study 24753053 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of a new stent
Number of subjects: 205
Study 24753053 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial TIMI 3 flow at index ST
Number of subjects: 205
Study 24753538 — intervention group
Group type: EXPERIMENTAL
Intervention: iC9-modified T cells
Number of subjects: 10
Study 24753695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV) - 2 doses with a 2-week interval
Number of subjects: 20
Study 24754273 — intervention group
Group type: EXPERIMENTAL
Intervention: IV abatacept (10 mg/kg weight-tiered dosing) with MTX (up to 8 mg/week)
Number of subjects: 217
Study 24754273 — intervention group
Group type: EXPERIMENTAL
Intervention: IV abatacept (10 mg/kg weight-tiered dosing) monotherapy
Number of subjects: 217
Study 24754273 — intervention group
Group type: EXPERIMENTAL
Intervention: IV abatacept (10 mg/kg weight-tiered dosing) with and without background MTX
Number of subjects: 217
Study 24754279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol stent implantation
Number of subjects: 196
Study 24754280 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC self-expanding nitinol stent system
Number of subjects: 125
Study 24754288 — intervention group
Group type: EXPERIMENTAL
Intervention: TruePath device
Number of subjects: 13
Study 24754838 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100U
Number of subjects: 0
Study 24754838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24755158 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures from the BOLD cohort registry
Number of subjects: 5239
Study 24755158 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare site as a factor
Number of subjects: 5239
Study 24755296 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 750 mg/m2 twice a day during days 1-7, oxaliplatin 85 mg/m2 and bevacizumab 5 mg/kg on day 1, repeated every 14 days
Number of subjects: 48
Study 24755296 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin and bevacizumab combination
Number of subjects: 48
Study 24755302 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular contrast injection with rotational C-arm CT (LV-RCT)
Number of subjects: 52
Study 24755302 — intervention group
Group type: COMPARATOR
Intervention: Aortic contrast injection with rotational C-arm CT (Ao-RCT)
Number of subjects: 52
Study 24755610 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR cartridge
Number of subjects: 12
Study 24755610 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR
Number of subjects: 12
Study 24755610 — intervention group
Group type: COMPARATOR
Intervention: HD
Number of subjects: 12
Study 24755610 — intervention group
Group type: COMPARATOR
Intervention: HFR and HD
Number of subjects: 12
Study 24756302 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical and laboratory features of IIH patients
Number of subjects: 165
Study 24756512 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMO weeks (ambulance-based thrombolysis)
Number of subjects: 6182
Study 24756512 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMO deployment
Number of subjects: 6182
Study 24756512 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMO weeks
Number of subjects: 6182
Study 24756936 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived MSCs (UC-MSCs)
Number of subjects: 0
Study 24756936 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow-derived MSCs from patients with active lupus
Number of subjects: 0
Study 24757132 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Disease Activity Score in 28 joints (M-DAS28)
Number of subjects: 0
Study 24757132 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Simplified Disease Activity Index (M-SDAI)
Number of subjects: 0
Study 24757132 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Clinical Disease Activity Index (M-CDAI)
Number of subjects: 0
Study 24757230 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaPep277
Number of subjects: 457
Study 24757230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 24758395 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive electrical stimulation of nerves
Number of subjects: 25
Study 24758527 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI® + bevacizumab (5 mg/kg bevacizumab, 180 mg/m2 irinotecan, 400 mg/m2 bolus FU, 400 mg/m2 leucovorin, followed by 46-hour FU infusions (2400 mg/m2))
Number of subjects: 62
Study 24758527 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFA polymorphism (rs25648)
Number of subjects: 62
Study 24758722 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient individual psychotherapy
Number of subjects: 113
Study 24758722 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down treatment program (including short-term day hospital treatment followed by combined group and individual psychotherapy)
Number of subjects: 113
Study 24758722 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (Outpatient and Step-down)
Number of subjects: 113
Study 24759933 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional tablets
Number of subjects: 132
Study 24759933 — intervention group
Group type: COMPARATOR
Intervention: Chewable tablets
Number of subjects: 132
Study 24759933 — intervention group
Group type: COMPARATOR
Intervention: Flavored powder
Number of subjects: 132
Study 24759933 — intervention group
Group type: COMPARATOR
Intervention: Unflavored powder
Number of subjects: 132
Study 24760136 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 34
Study 24760136 — intervention group
Group type: COMPARATOR
Intervention: OS alone or IVF
Number of subjects: 34
Study 24760402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine 8 mg (normal renal function and mild renal impairment)
Number of subjects: 32
Study 24760402 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5412 2 mg (moderate renal impairment and ESRD)
Number of subjects: 32
Study 24760402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine (single oral dose)
Number of subjects: 32
Study 24760402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 32
Study 24760972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cubans (n = 2128)
Number of subjects: 13285
Study 24760972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexicans (n = 5371)
Number of subjects: 13285
Study 24760972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominicans (n = 1217)
Number of subjects: 13285
Study 24760972 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerto Ricans (n = 2176)
Number of subjects: 13285
Study 24760972 — intervention group
Group type: EXPERIMENTAL
Intervention: Central and South Americans (n = 1468 and 925, respectively)
Number of subjects: 13285
Study 24761968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and rituximab (3 induction cycles of weekly administration)
Number of subjects: 42
Study 24762806 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of pacing stimuli needed to entrain (NNE)
Number of subjects: 30
Study 24762806 — intervention group
Group type: EXPERIMENTAL
Intervention: NNE with pacing cycle length and coupling interval
Number of subjects: 30
Study 24762806 — intervention group
Group type: EXPERIMENTAL
Intervention: NNE correlation with PPI and tachycardia cycle length
Number of subjects: 30
Study 24762806 — intervention group
Group type: EXPERIMENTAL
Intervention: NNE ≤2 and >3 predictions
Number of subjects: 30
Study 24762806 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrainment attempts changing or terminating tachycardia
Number of subjects: 30
Study 24762806 — intervention group
Group type: EXPERIMENTAL
Intervention: NNE as a mapping criterion
Number of subjects: 30
Study 24763770 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy for depression
Number of subjects: 0
Study 24763923 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FVIIa
Number of subjects: 0
Study 24763923 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24763965 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (n=186)
Number of subjects: 281
Study 24763965 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (n=95)
Number of subjects: 281
Study 24763965 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 281
Study 24764034 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT evaluation
Number of subjects: 35
Study 24764034 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-based therapy (40 mg to 50 mg prednisone per day)
Number of subjects: 35
Study 24764124 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888) 40 mg twice daily on days 1-7 and temozolomide (TMZ) 150 mg/m(2)/day for cycle 1, then 200 mg/m(2)/day for cycle 2 onwards on days 1-5 q28 days.
Number of subjects: 26
Study 24764124 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib and TMZ combination treatment.
Number of subjects: 26
Study 24764221 — intervention group
Group type: EXPERIMENTAL
Intervention: Galsulfase ERT
Number of subjects: 121
Study 24765228 — intervention group
Group type: COMPARATOR
Intervention: Ingenol mebutate gel 0.01%
Number of subjects: 332
Study 24766056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of alcohol withdrawal
Number of subjects: 47
Study 24766669 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Physical Activity (PA)
Number of subjects: 468
Study 24766669 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured Physical Activity (PA)
Number of subjects: 468
Study 24766669 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching TV and videos (Sedentary Behaviour)
Number of subjects: 468
Study 24766669 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting (Sedentary Behaviour)
Number of subjects: 468
Study 24766766 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester (STAEST) intervention, doses varied from 0.8 to 8.8 g/d, duration from 4 to 52 weeks.
Number of subjects: 868
Study 24766766 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester (STAEST) intervention
Number of subjects: 868
Study 24766985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized patients with AF
Number of subjects: 9484
Study 24766985 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 9484
Study 24766985 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate at baseline
Number of subjects: 9484
Study 24766985 — intervention group
Group type: EXPERIMENTAL
Intervention: AF symptom class
Number of subjects: 9484
Study 24767767 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus OTU 1345
Number of subjects: 55
Study 24767767 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus OTU 1348
Number of subjects: 55
Study 24768093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives
Number of subjects: 0
Study 24768093 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombosis prophylaxis during pregnancy
Number of subjects: 0
Study 24768093 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hereditary thrombophilia
Number of subjects: 0
Study 24768093 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 0
Study 24768457 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength intervention
Number of subjects: 0
Study 24768457 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24768795 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ischemic stroke (AIS) patients
Number of subjects: 168
Study 24768965 — intervention group
Group type: COMPARATOR
Intervention: African American ethnicity
Number of subjects: 12490
Study 24769012 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (70-80% maximum volume of oxygen utilization) for 12 weeks
Number of subjects: 44
Study 24769012 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy parous women)
Number of subjects: 44